Lv41
520 积分 2025-10-16 加入
Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series
13天前
已完结
ENGOT-ov62 - reducing chemotherapy duration in high-grade advanced ovarian cancer: A comparison of 3 vs. 6 cycles of platinum-based chemotherapy followed by niraparib maintenance in HRD-positive patients
16天前
已关闭
Efgartigimod alfa
23天前
已关闭
Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib
28天前
已关闭
A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer
1个月前
已完结
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Ribociclib-induced autoimmune-like hepatitis: a case report
1个月前
已完结
Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
1个月前
已完结
Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
1个月前
已完结
Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
1个月前
已完结
皖公网安备34019202002308
